Voyager sets sail for first tau gene therapy after FDA clearance (opens in new tab)

Alzheimer’s research may be entering its next chapter as Voyager advances a one-time therapy designed to reduce tau in the brain. For much of the last two decades, Alzheimer’s drug development has targeted amyloid, clearing the plaques and hoping cognition follows. However, what if the industry’s attention has been fixed on the wrong villain? Massachusetts-based […] The post appeared first on <a href="